Early erythropoiesis-stimulating agents in preterm or low birth weight infants

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 2, 2020, Pages

  Ohlsson, Arne ^a   Aher, Sanjay M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Dr Aher's Neocare Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; EPO PROTEIN, HUMAN;

ALL CAUSE MORTALITY; BLOOD DONOR; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CEREBRAL PALSY; DRUG EFFICACY; DRUG SAFETY; EMOTION; ENCEPHALOMALACIA; ERYTHROCYTE TRANSFUSION; EXECUTIVE FUNCTION; GRAY MATTER; HEARING IMPAIRMENT; HEMANGIOMA; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HUMAN; HYPERTENSION; INFANT; INFANT MORTALITY; LENGTH OF STAY; LOW BIRTH WEIGHT; LUNG DYSPLASIA; META ANALYSIS; NECROTIZING ENTEROCOLITIS; NEUTROPENIA; PREMATURITY; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; REVIEW; SEPSIS; SIDE EFFECT; SOCIAL BEHAVIOR; SURVIVOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL IMPAIRMENT; WHITE MATTER INJURY; WORKING MEMORY; BLOOD; ERYTHROPOIESIS; NEWBORN; NEWBORN ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA, NEONATAL; ENTEROCOLITIS, NECROTIZING; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOPATHY OF PREMATURITY;

EID: 85079337382     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004863.pub6     Document Type: Review

References (130)

1. Arif B, Ferhan K. Recombinant human erythropoietin therapy in low-birthweight preterm infants: a prospective controlled study. Pediatrics International 2005;47(1):67-71. [DOI: 10.1111/j.1442-200x.2005.02007.x; PUBMED: 15693870]x-wiley/crsRef/3082419
2. Avent M, Cory BJ, Galpin J, Ballot DE, Cooper PA, Sherman G, et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics 2002;48(4):227-33. [PUBMED: 12200985]x-wiley/crsRef/3082421
3. Carnielli V, Montini G, Da Riol R, Dall'Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics 1992;121(1):98-102. [PUBMED: 1625101]x-wiley/crsRef/3082423
4. Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 1998;79(1):F44-8. [PUBMED: 9797624]x-wiley/crsRef/3082425
5. Chang L, Liu W, Liao C, Zhao X. Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao 1998;18(4):239-42. [PUBMED: 10806855]x-wiley/crsRef/3082427
6. El-Ganzoury MM, Awad HA, El-Farrash RA, El-Gammasy TM, Ismail EA, Mohamed HE, et al. Enteral granulocyte-colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics 2014;165(6):1140-5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966]x-wiley/crsRef/7067178
7. Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122(2):375-82. [DOI: 10.1542/peds.2007-2591; PUBMED: 18676556]x-wiley/crsRef/3082429
8. Fauchère JC, Koller BM, Tschopp A, Dame C, Ruegger C, Bucher HU, Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high-dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics 2015;167(1):52-7.e1-3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661]x-wiley/crsRef/7067180
9. Leuchter RH, Gui L, Poncet A, Hagmann C, Lodygensky GA, Martin E, et al. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA 2014;312(8):817-24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725]x-wiley/crsRef/7067181
10. Natalucci G, Latal B, Koller B, Ruegger C, Sick B, Held L, et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high-dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA 2016;315(19):2079-85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300]x-wiley/crsRef/7067182
11. O'Gorman RL, Bucher HU, Held U, Koller BM, Huppi PS, Hagmann CF, et al. Swiss EPO Neuroprotection Trial Group. Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain 2015;138(Pt 2):388-97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356]x-wiley/crsRef/7067183
12. Haiden N, Cardona F, Schwindt J, Berger A, Kuhle S, Homoncik M, et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis 2005;93(1):118-23. [DOI: 10.1160/TH04-02-0093; PUBMED: 15630501]x-wiley/crsRef/3082431
13. He JS, Huang ZL, Yang H, Weng KZ, Zhu SB. Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics] 2008;10(5):586-8. [PUBMED: 18947475]x-wiley/crsRef/3082433
14. Khatami SF, Mamouri G, Torkaman M. Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics 2008;75(12):1227-30. [DOI: 10.1007/s12098-008-0225-0; PUBMED: 19057854]x-wiley/crsRef/3082435
15. Kremenopoulos G, Soubasi V, Tsantali C, Diamanti E, Tsakiris D. The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology 1997;4(4):373-83. [EMBASE: 1997362607]x-wiley/crsRef/7067185
16. Kremenopoulos G, Soubasi V, Tsantali C, Diamanti E, Tsakiris D. The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology 1997;4(4):373-83. [EMBASE: 1997362607]x-wiley/crsRef/7067187
17. Lauterbach R, Kachlik P, Pawlik D, Bajorek I. Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska 1995;70(9):739-44. [PUBMED: 8657506]x-wiley/crsRef/3082437
18. Lima-Rogel V, Torres-Montes A, Espinosa Griesse S, Villegas Alvarez C, Hernandez-Sierra F, Bissett Mandeville P, et al. Efficacy of early erythropoietin use in critically ill very-low-birth-weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre 1998;43(3):191-5. [PUBMED: 9741224]x-wiley/crsRef/3082439
19. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine 1994;330(17):1173-8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627]x-wiley/crsRef/3082441
20. Maier RF, Obladen M, Muller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics 2002;141(1):8-15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844]x-wiley/crsRef/3082443
21. Meister B, Maurer H, Simma B, Kern H, Ulmer H, Hittmair A, et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells 1997;15(5):359-63. [DOI: 10.1002/stem.150359; PUBMED: 9323798]x-wiley/crsRef/3082445
22. Meyer MP, Sharma E, Carsons M. Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 2003;88(1):F41-5. [PUBMED: 12496225]x-wiley/crsRef/3082447
23. Obladen M, Maier R, Segerer H, Grauel EL, Holland BM, Stewart G, et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology 1991;88:314-26. [PUBMED: 2040194]x-wiley/crsRef/3082449
24. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. Journal of Pediatrics 1995;126(3):421-6. [PUBMED: 7869205]x-wiley/crsRef/3082451
25. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo-controlled study. Journal of Pediatrics 1997;131(5):661-5. [PUBMED: 9403642]x-wiley/crsRef/3082453
26. Ehrenkranz RA, Ohls RK, Das A, Vohr BR. Neurodevelopmental outcome and growth at 18-22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research 2002;51:291A. x-wiley/crsRef/3082455
27. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004;114(5):1287-91. x-wiley/crsRef/7067188
28. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004;114(5):1287-91. [DOI: 10.1542/peds.2003-1129-L; PUBMED: 15520109]x-wiley/crsRef/3082456
29. Ohls RK, Ehrenkranz RA, Lemons JA, Korones SB, Stoll BJ, Stark AR, et al. A multicenter randomized double-masked placebo-controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research 1999;45:216A. x-wiley/crsRef/3082457
30. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108(4):934-42. [PUBMED: 11581447]x-wiley/crsRef/3082458
31. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108(4):934-42. [PUBMED: 11581447]x-wiley/crsRef/7067190
32. Lowe JR, Rieger RE, Moss NC, Yeo RA, Winter S, Patel S, et al. Impact of erythropoiesis-stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics 2017;184:75-80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625]x-wiley/crsRef/7067191
33. Ohls RK, Cannon DC, Phillips J, Caprihan A, Patel S, Winter S, et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics 2016;137(3):e20153859. [DOI: 10.1542/peds.2015-3859; PUBMED: 26908704]x-wiley/crsRef/7067192
34. Ohls RK, Christensen RD, Kamath-Rayne BD, Rosenberg A, Wiedmeier SE, Roohi M, et al. A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics 2013;132(1):e119-27. [DOI: 10.1542/peds.2013-0143; PUBMED: 23776118]x-wiley/crsRef/3082462
35. Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Fuller J, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics 2014;133(6):1023-30. [PUBMED: 24819566]x-wiley/crsRef/3082463
36. Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Schrader R, et al. Neurocognitive outcomes at 18-22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E-PAS2013:1165.5. x-wiley/crsRef/3082464
37. Ohls RK, McConaghy S, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18-22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E-PAS2013:2924.485. x-wiley/crsRef/3082465
38. Peltoniemi OM, Anttila E, Kaukola T, Buonocore G, Hallman M. Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development 2017;109:44-9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798]x-wiley/crsRef/7067194
39. Qiao L, Tang Q, Zhu W, Zhang H, Zhu Y, Wang H. Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine 2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850]x-wiley/crsRef/7067196
40. Salvado A, Ramolfo P, Escobar M, Nunez A, Aguayo I, Standen J, et al. Early erythropoietin use for the prevention of anemia in infant premature [Uso precoz de la eritropoyetina en la prevencion de la anemia del prematuro]. Revista Medica de Chile 2000;128(12):1313-7. [PUBMED: 11227239]x-wiley/crsRef/3082469
41. Song J, Sun H, Xu F, Kang W, Gao L, Guo J. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology 2016;80(1):24-34. [DOI: 10.1002/ana.24677; PUBMED: 27130143]x-wiley/crsRef/7067198
42. Soubasi V, Kremenopoulos G, Diamandi E, Tsantali C, Tsakiris D. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research 1993;34(5):675-9. [DOI: 10.1203/00006450-199311000-00022; PUBMED: 8284109]x-wiley/crsRef/3082473
43. Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics 1995;127(2):291-7. [PUBMED: 7636658]x-wiley/crsRef/3082475
44. Soubasi V, Kremenopoulos G, Tsantali C, Savopoulou P, Mussafiris C, Dimitrou M. Use of erythropoietin and its effects on blood lactate and 2,3-diphosphoglycerate in premature neonates. Biology of the Neonate 2000;78(4):281-7. [DOI: 14280; PUBMED: 11093007]x-wiley/crsRef/3082477
45. Yasmeen BHN, Chowdhury MA, Hoque MM, Hossain MM, Jahan R, Aktar S. Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin 2012;38(3):119-23. [PUBMED: 23540189]x-wiley/crsRef/3082479
46. Yeo CL, Choo S, Ho LY. Effect of recombinant human erythropoietin on transfusion needs in preterm infants. Journal of Paediatrics and Child Health 2001;37(4):352-8. [PUBMED: 11532054]x-wiley/crsRef/3082481
47. Al Mofada SM. Safety and efficacy of early erythropoietin administration to pre-term infants: a preliminary report. Medical Science Research 1994;22(10):749-50. [EMBASE: 1994345936]x-wiley/crsRef/7067200
48. Amin AA, Alzahrani DM. Efficacy of erythropoietin in premature infants. Saudi Medical Journal 2002;23(3):287-90. [PUBMED: 11938417]x-wiley/crsRef/3082483
49. Basiri B, Shokouhi M, Pezeshki N, Torabian S. Beneficial erythropoietic effects of recombinant human erythropoietin in very low-birth weight infants: a single-center randomized double-blinded placebo-controlled trial. Journal of Clinical Neonatology 2015;4(2):87-90. [EMBASE: 2015952409]x-wiley/crsRef/7067202
50. Bierer R, Peceney MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006;118(3):e635-40. [DOI: 10.1542/peds.2005-3186; PUBMED: 16908620]x-wiley/crsRef/3082485
51. Brown MS, Keith JF 3rd. Comparison between two and five doses a week of recombinant erythropoietin for anemia of prematurity: a randomized trial. Pediatrics 1999;104(2 Pt 1):210-5. [PUBMED: 10428996]x-wiley/crsRef/3082487
52. Costa S, Romagnoli C, Zuppa AA, Cota F, Socorrano A, Gallini F, et al. How to administrate erythropoietin, intravenous or subcutaneous?. Acta Paediatrica 2013;102(6):579-83. [DOI: 10.1111/apa.12193; PUBMED: 23414120]x-wiley/crsRef/3082489
53. Fearing MK, Eades B, Martinez B, Wood N, Accardo L, Browning CA, et al. Cost effective use of recombinant erythropoietin (HuEPO) in very low birth weight (VLBW) infants for improved clinical outcomes. Pediatric Research 2002;51:310A. x-wiley/crsRef/3082491
54. 12 on the transfusion requirements of extremely low birth weight infants. Pediatrics 2006;118(5):2004-13. [DOI: 10.1542/peds.2006-1113; PUBMED: 17079573]x-wiley/crsRef/3082493
55. Haiden N, Klebermass K, Cardona F, Schwindt J, Berger A, Kohlhauser-Vollmuth C, et al. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics 2006;118(1):180-8. [DOI: 10.1542/peds.2005-2475; PUBMED: 16818564]x-wiley/crsRef/3082495
56. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122(2):383-91. [DOI: 10.1542/peds.2007-2711; PUBMED: 18676557]x-wiley/crsRef/3082497
57. Klipp M, Holzwarth AU, Poeschl JM, Nelle M, Linderkamp O. Effects of erythropoietin on erythrocyte deformability in non-transfused preterm infants. Acta Paediatrica 2007;96(2):253-6. [PUBMED: 17429915]x-wiley/crsRef/3082499
58. Krallis N, Cholevas V, Mavridis A, Georgiou I, Bourantas K, Andronikou S. Effect of recombinant human erythropoietin in preterm infants. European Journal of Haematology 1999;63(2):71-6. [PUBMED: 10480285]x-wiley/crsRef/3082501
59. López-Catzín JF, Bolado-García PB, Gamboa-López GJ, Medina-Escobedo CE, Cambranes-Catzima LR. Decreased transfusions in preterm infants with anemia treated with erythropoietin [Disminución de transfusiones en prematuros con anemia tratados con eritropoyetina]. Revista Medica del Instituto Mexicano del Seguro Social 2016;54(5):576-80. [PUBMED: 27428338]x-wiley/crsRef/7067204
60. Maggio L, Scorrano A, Cota F, Gallini F, Romagnoli C, Zuppa AA. Randomized controlled trial on the effectiveness of early recombinant erythropoietin administered to preterm infants by continuous intravenous versus subcutaneous route. Pediatric Academic Societies' Annual Meeting 2007. 2007:E-PAS2007:616315.9. x-wiley/crsRef/3082503
61. Maier RF, Obladen M, Kattner E, Natzschka J, Messer J, Regazzoni BM, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. Journal of Pediatrics 1998;132(5):866-70. [PUBMED: 9602202]x-wiley/crsRef/3082505
62. Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. Journal of Pediatrics 1996;128(4):518-23. [PUBMED: 8618186]x-wiley/crsRef/3082507
63. Saeidi R, Banihashem A, Hammoud M, Gholami M. Comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity. Iranian Red Crescent Medical Journal 2012;14(3):178-81. [PUBMED: 22737576]x-wiley/crsRef/3082509
64. Soubasi V, Pouliou T, Tsantali C, Lithoxopoulou M, Drossou V, Kremenopoulos G. Is erythropoietin (EPO) a multifunctional tissue protective cytokine? Follow-up of rHuEPO treated prematures. Pediatric Academic Societies' Annual Meeting 2005. 2005:PAS 2005;57:164. x-wiley/crsRef/3082511
65. Soubasi V, Petridou S, Sarafidis K, Agathi T, Griva M, Drossou V. High dose of erythropoietin in premature neonates: short-term outcomes. Pediatric Academic Societies' Annual Meeting 2009. 2009:E-PAS 2009;5506:105. x-wiley/crsRef/3082513
66. Turker G, Sarper N, Gokalp S, Usluer H. The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants. American Journal of Perinatology 2005;22(8):449-55. [DOI: 10.1055/s-2005-918888; PUBMED: 16283605]x-wiley/crsRef/3082515
67. Vázquez López MÁ, Llamas MÁ, Galera R, Sanchez AR, Lendinez F, Gonzalez-Ripoll M, et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. Journal of Perinatology 2011;31(2):118-24. [DOI: 10.1038/jp.2010.80; PUBMED: 20689518]x-wiley/crsRef/3082517
68. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124(2):e218-26. [DOI: 10.1542/peds.2008-3553; PUBMED: 19651565]x-wiley/crsRef/3082519
69. NCT01378273. Preterm Erythropoietin Neuroprotection Trial (PENUT Trial). clinicaltrials.gov/show/NCT01378273 (first received 20 June 2011). x-wiley/crsRef/7067206
70. NCT02550054. Erythropoietin in Premature Infants to Prevent Encephalopathy [Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi-centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China]. clinicaltrials.gov/show/NCT02550054 (first received 04 September 2015). x-wiley/crsRef/7067208
71. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004868.pub2]
72. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004865.pub2]
73. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD004868.pub3]
74. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD004865.pub2]
75. Baer VL, Lambert DK, Henry E, Snow GL, Christensen RD. Red blood cell transfusion of preterm neonates with grade 1 intraventricular hemorrhage is associated with extension to a grade 3 or 4 hemorrhage. Transfusion 2011;51(9):1933-9. [DOI: 10.1111/j.1537-2995.2011.03081.x; PUBMED: 21382049]
76. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, et al. Trial of Indomethacin Prophylaxis in Preterm Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009;123(1):313-8. [DOI: 10.1542/peds.2008-0377; PUBMED: 19117897]
77. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. [PUBMED: 8773637]
78. Blau J, Calo JM, Dozor D, Sutton M, Alpan G, La Gamma EF. Transfusion-related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. Journal of Pediatrics 2011;158(3):403-9. [DOI: 10.1016/j.jpeds.2010.09.015; PUBMED: 21067771]
79. Brown MS, Phibbs RH, Garcia JF, Dallman PR. Postnatal changes in erythropoietin levels in untransfused premature infants. Journal of Pediatrics 1983;103(4):612-7. [PUBMED: 6194281]
80. Brown MS, Berman ER, Luckey D. Prediction of the need for transfusion during anemia of prematurity. Journal of Pediatrics 1990;116(5):773-8.
81. Chou HH, Chung MY, Zhou XG, Lin HC. Early erythropoietin administration does not increase the risk of retinopathy in preterm infants. Pediatrics and Neonatology 2017;58(1):48-56. [DOI: 10.1016/j.pedneo.2016.03.006; PUBMED: 27346390]
82. Cohen A, Manno C. Transfusion practices in infants receiving assisted ventilation. Clinics in Perinatology 1998;25(1):97-111. [PUBMED: 9523077]
83. Dallman PR. Anemia of prematurity. Annual Review of Medicine 1981;32:143-60. [DOI: 10.1146/annurev.me.32.020181.001043; PUBMED: 7013658]
84. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biology of the Neonate 2001;79(3-4):228-35. [DOI: 47097; PUBMED: 11275657]
85. Dolfin T, Skidmore MB, Fong KW, Hoskins EM, Shennan AT. Incidence, severity, and timing of subependymal and intraventricular hemorrhages in preterm infants born in a perinatal unit as detected by serial real-time ultrasound. Pediatrics 1983;71(4):541-6. [PUBMED: 6835737]
86. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 2001;84(Suppl 1):3-10. [DOI: 10.1054/bjoc.2001.1746; PUBMED: 11308268]
87. Finch CA. Erythropoiesis, erythropoietin and iron. Blood 1982;60:1241-6. [PUBMED: 6753967]
88. Fischer HS, Reibel NJ, Bührer C, Dame C. Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta-analysis. Pediatrics 2017;139(5):e20164317. [DOI: 10.1542/peds.2016-4317; PUBMED: 28557760]
89. Garcia MG, Hutson AD, Christensen RD. Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis. Journal of Perinatology 2002;22(2):108-11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514]
90. McMaster University (developed by Evidence Prime), 2015. GRADEpro GDT. Version accessed 06 March 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015., 2015.
91. Hesse L, Eberl W, Schlaud M, Poets CF. Blood transfusion. Iron load and retinopathy of prematurity. European Journal of Pediatrics 1997;156(6):465-70. [PUBMED: 9208245]
92. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557; PUBMED: 12958120]
93. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
94. Juul SE. Erythropoietin in the neonate. Current Problems in Pediatrics 1999;29(5):133-49. [PUBMED: 10331138]
95. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatrica Supplement 2002;91(438):36-42. [PUBMED: 12477263]
96. Juul S. Neuroprotective role of erythropoietin in neonates. Journal of Maternal-Fetal & Neonatal Medicine 2012;25(Suppl 4):105-7. [DOI: 10.3109/14767058.2012.715025; PUBMED: 22958035]
97. Kirpalani H, Zupancic JA. Do transfusions cause necrotizing enterocolitis? The complementary role of randomized trials and observational studies. Seminars in Perinatology 2012;36(4):269-76. [DOI: 10.1053/j.semperi.2012.04.007; PUBMED: 22818547]
98. Klaus MH, Fanaroff AA. Care of the High-risk Neonate. 3rd Edition. Philadelphia, London, Toronto: W.B. Saunders Campany, 1986.
99. Klaus M, Fanaroff A. Asistencia del Recien Nacido de Alto Riesgo. 3rd Edition. Colombia: Panamericana, 1987.
100. Kotto-Kome AC, Garcia MG, Calhoun DA, Christensen RD. Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: a meta-analysis. Journal of Perinatology 2004;24(1):24-9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934]
101. Kumral A, Tuzun F, Oner MG, Genç S, Duman N, Özkan H. Erythropoietin in neonatal brain protection: the past, the present and the future. Brain & Development 2011;33(8):632-43. [DOI: 10.1016/j.braindev.2010.10.014; PUBMED: 21109375]
102. Limperopoulos C. Neuroprotective effects of erythropoietin in preterm infants. Nature Reviews. Neurology 2010;6(6):301-2. [DOI: 10.1038/nrneurol.2010.66; PUBMED: 20531428]
103. Messier AM, Ohls RK. Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates. Current Opinion in Pediatrics 2014;26(2):139-45. [DOI: 10.1097/MOP.0000000000000077; PUBMED: 24535496]
104. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Annals of Neurology 2010;67(5):657-66. [DOI: 10.1002/ana.21977; PUBMED: 20437563]
105. Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. Journal of Perinatology 1999;19(6 Pt 1):403-6. [PUBMED: 10685268]
106. Ohls RK. The use of erythropoietin in neonates. Clinics in Perinatology 2000;27(3):681-96. [PUBMED: 10986635]
107. Ohls RK. Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. Journal of Pediatrics 2002;141(1):3-6. [DOI: 10.1067/mpd.2002.125853; PUBMED: 12091842]
108. Ohls RK. Why study erythropoietin in preterm infants?. Acta Paediatrica 2013;102(6):567-8. [DOI: 10.1111/apa.12234; PUBMED: 23551714]
109. Patel S, Ohls RK. Darbepoetin administration in term and preterm neonates. Clinics in Perinatology 2015;42(3):557-66. [DOI: 10.1016/j.clp.2015.04.016; PUBMED: 26250917]
110. Rangarajan V, Juul SE. Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection. Pediatric Neurology 2014;51(4):481-8. [DOI: 10.1016/j.pediatrneurol.2014.06.008; PUBMED: 25266611]
111. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
112. Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF, et al. Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003;289(9):1124-9. [PUBMED: 12622582]
113. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Available from https://gdt.gradepro.org/app/handbook/handbook.html. Updated October 2013.
114. Shannon KM. Recombinant human erythropoietin in neonatal anemia. Clinics in Perinatology 1995;22(3):627-40. [PUBMED: 8521685]
115. Sharp M, DeMauro SB. Counterbalanced comparison of the BSID-II and Bayley-III at eighteen to twenty-two months corrected age. Journal of Developmental and Behavioral Pediatrics 2017;38(5):322-9. [DOI: 10.1097/DBP.0000000000000441; PUBMED: 28538042]
116. Shiou SR, Yu Y, Chen S, Ciancio MJ, Petrof EO, Sun J, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. Journal of Biological Chemistry 2011;286(14):12123-32. [DOI: 10.1074/jbc.M110.154625; PUBMED: 21262973]
117. Stockman JA 3rd, Oski FA. Physiological anaemia of infancy and the anaemia of prematurity. Clinics in Haematology 1978;7(1):3-18. [PUBMED: 657601]
118. Stockman JA 3rd. Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatric Clinics of North America 1986;33(1):111-28. [PUBMED: 3513096]
119. Strauss RG. Current issues in neonatal transfusions. Vox Sanguinis 1986;51(1):1-9. [PUBMED: 3526725]
120. Vamvakas EC, Strauss RG. Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion 2001;41(3):406-15. [PUBMED: 11274599]
121. Wang H, Zhang L, Jin Y. A meta-analysis of the protective effect of recombinant human erythropoietin (rhEPO) for neurodevelopment in preterm infants. Cell Biochemistry and Biophysics 2015;71(2):795-802. [DOI: 10.1007/s12013-014-0265-1; PUBMED: 25300689]
122. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH, et al. Single-dose darbepoetin administration to anemic preterm neonates. Journal of Perinatology 2005;25(11):725-30. [DOI: 10.1038/sj.jp.7211387; PUBMED: 16151471]
123. Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD000512.pub2]
124. Widness JA, Seward VJ, Kromer IJ, Burmeiser LF, Bell EF, Strauss RG. Changing patterns of red blood cell transfusion in very low birth weight infants. Journal of Pediatrics 1996;129(5):680-7. [PUBMED: 8917234]
125. Xu XJ, Huang HY, Chen HL. Erythropoietin and retinopathy of prematurity: a meta-analysis. European Journal of Pediatrics 2014;173(10):1355-64. [DOI: 10.1007/s00431-014-2332-4; PUBMED: 24849614]
126. Zhang J, Wang Q, Xiang H, Xin Y, Chang M, Lu H. Neuroprotection with erythropoietin in preterm and/or low birth weight infants. Journal of Clinical Neuroscience 2014;21(8):1283-7. [DOI: 10.1016/j.jocn.2013.10.040; PUBMED: 24650681]
127. Zipursky A. Erythropoietin therapy for premature infants: cost without benefit?. Pediatric Research 2000;48(2):136. [DOI: 10.1203/00006450-200008000-00002; PUBMED: 10926284]
128. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004863.pub2]
129. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD004863.pub3]
130. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD004863.pub4]